Xcout IntelAdial Pharmaceuticals, Inc competitors & alternatives
The 12 closest competitors and alternatives to Adial Pharmaceuticals, Inc among biotechnology companies — ranked by similarity to what Adial Pharmaceuticals, Inc actually does, not by market-cap band.
Subscribe to see Adial Pharmaceuticals, Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Adial Pharmaceuticals, Inc
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc at a glance
Adial Pharmaceuticals, Inc is a biotechnology company headquartered in Glen Allen, United States. It is publicly listed (ADIL) with a market capitalisation of $2.7M. Xcout tracks 26 named people at Adial Pharmaceuticals, Inc, including Cary John Claiborne (Chief Executive Officer, President & Director).
Adial Pharmaceuticals, Inc leadership
- Cary John ClaiborneChief Executive Officer, President & Director
- Cary J ClaiborneChief Executive Officer
- Vinay ShahChief Financial Officer & Treasurer
- John R. MartinChief Legal Officer
- Matthew DavidsonChief Development Officer & Director
- Jay KernFounder and General Partner of Kern Capital
20 more named people on record for Adial Pharmaceuticals, Inc, with roles, board committees and tenure — see the full roster →
Top 12 Adial Pharmaceuticals, Inc competitors
Ranked by semantic similarity — how close each company is to Adial Pharmaceuticals, Inc by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Navion Neurosciences, Inc. is a preclinical-stage biotechnology company located in Charlottesville, Virginia, that is developing next-generation, AI-enabled therapies.
Similar biotechnology company
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Biotech
NFL Biosciences develops botanical drug candidates derived from natural extracts to treat addictions, specifically targeting smoking cessation and the reduction of alcohol consumption. The company focuses on clinical-stage pharmaceutical research with the aim of licensing its innovative therapies to pharmaceutical partners.
Similar biotechnology company
Daya CNS, LLC is a preclinical biopharmaceutical company that develops a proprietary non-opioid pyridoindole platform for the treatment of chronic pain, substance abuse disorders, and neuropsychiatric conditions. Its product pipeline includes small molecule medications such as DDD-028 for neuropathic and inflammatory pain, DDD-024 for addiction, and DDD-016 for neuropsychiatric disorders, serving patients with unmet medical needs in neurology and addiction medicine.
Biotech
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Similar biotechnology company
Amalgent Therapeutics develops fixed-dose combination therapies that pair opioids with dopamine-modulating adjuvants to provide safe pain management. The company's lead program, AMGT-0220, is designed to reduce required opioid doses, mitigate tolerance development, and lower reward signaling to help patients recover without the risks of conventional opioid treatments.
Similar biotechnology company
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Biotech
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Biotech
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Biotech
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Biotech
Cara Therapeutics, Inc. is an emerging biopharmaceutical company with an initial commercial presence, dedicated to the development and commercialization of novel pharmaceutical compounds. Its core mission revolves around addressing pruritus (itching) and pain, primarily by selectively modulating kappa opioid receptors, with a particular focus on the United States. The company's therapeutic pipeline features agents designed to interact with the body's peripheral nervous system and immune cells. Its flagship therapy, KORSUVA (difelikefalin) injection, is approved for managing moderate-to-severe pruritus in adult hemodialysis patients suffering from chronic kidney disease (CKD). Beyond this, Cara Therapeutics is advancing Oral KORSUVA (difelikefalin), which has successfully completed Phase II clinical trials for pruritus associated with atopic dermatitis and non-dialysis-dependent chronic kidney disease (NDD-CKD). This oral formulation is also currently undergoing Phase II trials for pruritus linked to chronic liver disease (CLD), specifically primary biliary cholangitis (PBC), and for notalgia paresthetica. Globally, the company has established strategic license agreements: with Maruishi Pharmaceutical Co., Ltd. for the development, manufacturing, and commercialization of difelikefalin-containing drug products for acute pain and uremic pruritus in Japan; and with Chong Kun Dang Pharmaceutical Corporation for similar activities regarding difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Similar biotechnology company
Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel non-opioid therapeutics for the treatment of chronic pain and painful conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Adial Pharmaceuticals, Inc and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Adial Pharmaceuticals, Incand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →